Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Earnings for Evofem Biosciences, Inc. (EVFM)
Earnings in 2023 (TTM): $53 M
According to Evofem Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $53 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Evofem Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $53 M | $52.98 M |
| 2022 | $-76,654,000 | $-76,698,000 |
| 2021 | $-205,175,000 | $-205,192,000 |
| 2020 | $-142,305,000 | $-142,309,000 |
| 2019 | $-80,029,000 | $-80,033,000 |
| 2018 | $-125,710,000 | $-125,712,000 |
| 2017 | $-9,993,451 | $-9,993,451 |
| 2016 | $-13,018,598 | $-13,018,598 |
| 2015 | $-43,157,045 | $-43,157,045 |
| 2014 | $-10,819,236 | $-10,819,236 |
| 2013 | $-15,016,253 | $-15,016,253 |
| 2012 | $-7,827,616 | $-7,827,616 |